In a new study published in Nature Aging, researchers from the University of Arizona present a novel therapeutic target aimed at protecting nerve cells from amyotrophic lateral sclerosis (ALS). The study, titled “Therapeutic targeting of the conserved region within the low-complexity domain of TDP-43 is neuroprotective and extends survival in amyotrophic lateral sclerosis mice,” highlights the urgent need for breakthroughs in ALS treatment, as current FDA-approved options offer only modest benefits, according to Dr. Xinglong Wang, the study’s corresponding author.
ALS presents significant treatment challenges, primarily due to the advanced stage of nerve cell damage at the time of diagnosis. While the exact causes remain largely unknown, most cases exhibit abnormal aggregation of TDP-43 protein, which complicates the understanding of disease progression. The research team identified a specific region within the TDP-43 protein that harbors disease-causing mutations, and upon deletion of this region in mice, they observed a marked reduction in nerve cell death while preserving normal protein function.
The experimental drug XL20, which effectively targets this region, demonstrated a notable extension of median survival in mice by approximately one week and showed promise in reversing damage in human motor neurons. Dr. Wang emphasizes that XL20 could represent a significant advancement in clinical development, particularly if administered earlier in the disease course, thereby offering greater potential to slow progression. Furthermore, the implications of this research extend beyond ALS, as TDP-43 pathology is implicated in other neurodegenerative diseases, including certain dementias and Alzheimer’s disease, suggesting a broader impact on patient populations.
Get started today with Solo access →
